Zevra Therapeutics (ZVRA) Rises 10.4%: Is There More Growth Potential for the Stock?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 25 2025
0mins
Source: NASDAQ.COM
Zevra Therapeutics Stock Performance: Zevra Therapeutics (ZVRA) shares rose 10.4% to $8.95, reversing a 13.8% loss over the past month, driven by positive investor sentiment regarding its drug Miplyffa for Niemann-Pick disease type C.
Earnings and Revenue Expectations: The company is projected to report a quarterly loss of $0.04 per share, with revenues expected to reach $26.53 million, reflecting a significant year-over-year increase, while the consensus EPS estimate has remained stable.
AI Investment Insights: The article discusses the potential for significant wealth creation in the next phase of AI, suggesting that early investors in emerging companies may benefit as the growth of established AI stocks begins to level off.
Zacks Rank and Industry Context: Zevra Therapeutics holds a Zacks Rank of #3 (Hold), similar to Nektar Therapeutics, which has seen a notable increase in its stock price over the past month, highlighting trends within the medical-drugs industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZVRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZVRA
Wall Street analysts forecast ZVRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZVRA is 24.00 USD with a low forecast of 21.00 USD and a high forecast of 26.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.630
Low
21.00
Averages
24.00
High
26.00
Current: 8.630
Low
21.00
Averages
24.00
High
26.00
About ZVRA
Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. It has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Stonepine Capital Fully Exits ANI Pharmaceuticals, Reporting $2.52 Million Loss
- Full Exit: Stonepine Capital sold all 38,597 shares of ANI Pharmaceuticals in Q3, valued at approximately $2.52 million, marking a complete exit from the company as of September 30.
- Market Performance: Despite Stonepine's exit, ANI Pharmaceuticals' stock has risen 49% over the past year, currently priced at $82.41, significantly outperforming the S&P 500's 15% increase during the same period, indicating strong market competitiveness.
- Financial Growth: ANI Pharmaceuticals reported a 54% year-over-year revenue surge to $227.8 million in the latest quarter, with adjusted EBITDA jumping nearly 70% to $59.6 million, prompting management to raise full-year revenue guidance to $873 million.
- Investment Strategy Shift: The exit by Stonepine does not reflect a lack of confidence in ANI but rather a capital rotation, indicating a preference for earlier-stage biotech investments, which suggests a cautious outlook on ANI's future growth potential.
Continue Reading
Zevra Grants 53,000 Stock Options to Attract New Employees
- Employee Incentive Program: Zevra Therapeutics has granted a total of 53,000 stock options to three new employees under its 2023 Employment Inducement Award Plan, aimed at attracting talent and enhancing the company's competitive edge in rare disease treatment.
- Option Grant Details: Each stock option vests over four years, with 25% vesting in the first year and the remainder in three equal annual installments, which not only incentivizes long-term employee retention but also enhances team stability.
- Compliance Assurance: The stock option grants comply with Nasdaq Rule 5635(c)(4), ensuring that the company adheres to relevant regulations while attracting new employees, thereby reducing legal risks and boosting investor confidence.
- Mission Reinforcement: Zevra focuses on providing therapies for rare disease patients, and this incentive measure not only helps attract skilled professionals but also drives the company's innovative capabilities in complex drug development, furthering its mission.
Continue Reading